We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that,...
Cassava Sciences
Short Term - We look to Sell at 32.45 (stop at 36.81)
We look to sell rallies. Trading volume is increasing. Previous support, now becomes resistance at 32.00. We can see no technical reason for a change of trend. The bias is still for lower levels and we look for any gains to be limited.
Our profit targets will be 12.45 and 7.56...
SAVA is currently trading in a critical support zone. It just established it's first "higher low" since it's crash from $100. Further upward movement from here would likely lead to a test of $60. Downward movement, below $37, could prove disastrous. SAVA has established a "higher low" two other times since late 2020, both leading to large bull moves and a rumored...
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that the U.S. Food and Drug Administration ("FDA") denied a Citizen Petition that was filed in August 2021 by an attorney on behalf of short-selling clients. FDA also denied four supplements to the August 2021 Citizen Petition. FDA also...
Not a financial advisor.
Sava is looking to make its way up north - and potentially quick.
SAVA is looking to cross MAs this will be above $50 shortly. And potential to reach $100 fairly fast as well due to the pattern break out.
SAVA can see explosive movement - definitely a must watch here. This presents itself as a favorable trade and incredible long term...
Cassava Sciences Stock Is Worth Almost 4x More After Adjusting for Risk
* 1/10/2022 1:45pm EST
* By Mark R. Hake, CFA
Cassava Sciences (NASDAQ:SAVA) stands to gain a good deal this year. This will all depend on the company’s Phase 3 clinical trials progress in the results on actual patients with Alzheimer’s disease. SAVA stock could become a major winner as a...
sava seems like it can be stuck at this extreme support zone for a while. So lets wait for a clear breakout past local resistance or below extreme support.
over 60.83 my targets are 70.06-93.13, below 32 theres like no support! so my targets 10-15.
like and follow for more 💘
Just having a play around with some Bollinger Squeeze indicators that are free in the library.
Wonder if SAVA will repeat the same pattern as last time and give us a bit of a breakout.
Last run was on news, but I haven't seen any catalyst for this one. I don't think it will run anywhere near the last breakout, but might get something out of it.
Will be...
NASDAQ:SAVA
Negative head and Shoulders
DISCLAIMER:
I am not a financial /investment advisor. All information i am sharing here is for entertainment purposes only and should not be considered personal investment advice. While the information provided is accurate, it may include errors or inaccuracies. Please, do your diligence when it comes to investing or...
Today's action looks very corrective in action rather than a bull run. I think there is going to be on more leg down before it really goes back up again.
The upside will be limited to $65-$69 range and the final downside should be around $37. I am not in the trade right now but will see if need to be short at $65.
A sharp and unforgiving retracement however, technically the stock looks great. Price has respected Mid bollinger band and SuperTrend on the daily and the Ichomoku clouds signal brighter days ahead.
I don't like the price action Friday and today on this ticker and wasn't expecting it to come this low. The EW count isn't clear right now and i closed my position with a some profit's. Want to watch it for next few days and will share if i re-enter into it.
A quick brief, Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
Quick take on the price action for SAVA, the...
